254 related articles for article (PubMed ID: 37088954)
21. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
22. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.
Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468
[TBL] [Abstract][Full Text] [Related]
23. Dupilumab shows slow, steady effectiveness for intractable prurigo in patients with atopic dermatitis.
Takeuchi S; Inoue K; Kuretake K; Kiyomatsu-Oda M; Furue M
J Dermatol; 2021 May; 48(5):638-644. PubMed ID: 33742710
[TBL] [Abstract][Full Text] [Related]
24. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials.
Silverberg JI; Simpson EL; Ardeleanu M; Thaçi D; Barbarot S; Bagel J; Chen Z; Eckert L; Chao J; Korotzer A; Rizova E; Rossi AB; Lu Y; Graham NMH; Hultsch T; Pirozzi G; Akinlade B
Br J Dermatol; 2019 Jul; 181(1):80-87. PubMed ID: 30791102
[TBL] [Abstract][Full Text] [Related]
25. [Clinical observation on the efficacy and safety of dupilumab in the treatment of moderate to severe atopic dermatitis].
Li CY; Chen S; Qian WL; Yang L; Zheng Q; Chen AJ; Chen J; Huang K; Fang S; Wang P; Hu L; Liu XR; Zhao XQ; Tan N; Cai T
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Oct; 57(10):1590-1595. PubMed ID: 37859375
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M
J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
28. Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis.
Kwatra SG; Yosipovitch G; Ständer S; Guillemin I; Msihid J; Bansal A; Makhija M; Wiggins S; Zahn J; Thomas RB; Bahloul D
J Eur Acad Dermatol Venereol; 2024 May; ():. PubMed ID: 38785405
[TBL] [Abstract][Full Text] [Related]
29. Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan.
Murota H; Arima K; Yoshida T; Fujita H
J Dermatol; 2024 Feb; 51(2):223-233. PubMed ID: 38066728
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis.
Napolitano M; Fabbrocini G; Scalvenzi M; Nisticò SP; Dastoli S; Patruno C
Dermatitis; 2020; 31(1):81-84. PubMed ID: 31517666
[TBL] [Abstract][Full Text] [Related]
31. Dupilumab in Inflammatory Skin Diseases: A Systematic Review.
Olbrich H; Sadik CD; Ludwig RJ; Thaçi D; Boch K
Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189381
[TBL] [Abstract][Full Text] [Related]
32. Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.
Napolitano M; Fabbrocini G; Neri I; Stingeni L; Boccaletti V; Piccolo V; Amoruso GF; Malara G; De Pasquale R; Di Brizzi EV; Diluvio L; Bianchi L; Chiricozzi A; Di Guida A; Del Duca E; Moschese V; Di Lernia V; Dragoni F; Gruber M; Hansel K; Licari A; Manti S; Leonardi S; Mastorino L; Ortoncelli M; Provenzano E; Palermo A; Patella V; Peduto T; Pezzolo E; Piras V; Potestio L; Battista T; Satta R; Termine S; Palma P; Zangari P; Patruno C
Paediatr Drugs; 2022 Nov; 24(6):671-678. PubMed ID: 36028611
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
[TBL] [Abstract][Full Text] [Related]
34. A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis.
Napolitano M; Fabbrocini G; Potestio L; Fontanella G; Picone V; Bennardo L; Scalvenzi M; Patruno C
Dermatol Ther; 2022 Aug; 35(8):e15588. PubMed ID: 35569129
[TBL] [Abstract][Full Text] [Related]
35. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
Wang FP; Tang XJ; Wei CQ; Xu LR; Mao H; Luo FM
J Dermatol Sci; 2018 May; 90(2):190-198. PubMed ID: 29472119
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Abrocitinib in Prurigo Nodularis and Chronic Pruritus of Unknown Origin: A Nonrandomized Controlled Trial.
Kwatra SG; Bordeaux ZA; Parthasarathy V; Kollhoff AL; Alajmi A; Pritchard T; Cornman HL; Kambala A; Lee KK; Manjunath J; Ma EZ; Dillen C; Kwatra MM
JAMA Dermatol; 2024 Jun; ():. PubMed ID: 38837144
[TBL] [Abstract][Full Text] [Related]
37. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
38. Dupilumab Treatment for Prurigo Nodularis and Pruritis.
Tanis R; Ferenczi K; Payette M
J Drugs Dermatol; 2019 Sep; 18(9):940-942. PubMed ID: 31524352
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of dupilumab plus topical tacrolimus for atopic dermatitis in 6- to 12-year-old patients.
Gao SS; Chen M; Wang R; Chen JG
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):9830-9837. PubMed ID: 37916349
[TBL] [Abstract][Full Text] [Related]
40. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]